Xiaoyang Li

Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously

Jie Zang, Xuewu Liang, Yongxue Huang et al. · Journal of Medicinal Chemistry · 2018 · 102 citations · Full text

Histone Deacetylases, Angiogenesis Simultaneously, Chemoprevention Strategy +21

Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide Donor

Wenwen Duan, Jin Li, Elizabeth S. Inks et al. · Journal of Medicinal Chemistry · 2015 · 88 citations · Full text

Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status

Xiaoyang Li, Yuri K. Peterson, Elizabeth S. Inks et al. · Journal of Medicinal Chemistry · 2018 · 83 citations · Full text

Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies

Xuewu Liang, Jie Zang, Xiaoyang Li et al. · Journal of Medicinal Chemistry · 2019 · 81 citations · Full text

Discovery of the First <i>N</i>-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity

Xiaoyang Li, Elizabeth S. Inks, Xiaoguang Li et al. · Journal of Medicinal Chemistry · 2014 · 75 citations · Full text

Medicinal Chemistry, Representative Compound 14A, Histone Deacetylase 1/3 +13